- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, April 3, 2017 – Bayer’s biological nematicide BioAct™ Prime DC has been granted regulatory approval in Greece. The market launch in Greece is scheduled for 2017, with other European countries to follow as a measure to further strengthen the company's crop protection portfolio in this important region.
“To secure their harvests and increase food production in a sustainable matter, European farmers need modern technologies such as innovative crop protection products,” said Klaus Koetting, Head of Fruits & Vegetables and Insecticides at Crop Science, a division of Bayer. “Our biological nematicide BioAct Prime will contribute substantially to improved Integrated Pest Management programs.”
BioAct™ Prime DC, based on the beneficial fungus Paecilomyces lilacinus (synonym Purpureocilium lilacinum strain 251), controls plant parasitic nematodes including root-knot nematodes (Meloidogyne spp.), burrowing nematodes (Radopholus similis), cyst nematodes (Globodera spp.) and root lesion nematodes (Pratylenchus spp.). BioAct™ protects plants by targeting eggs and larvae of harmful nematodes before they can attack the roots, helping farmers to increase yields and farm profitability. The new nematicide can be used on a wide range of fruit and vegetable crops such as tomatoes, cucumbers, asparagus, avocado, beans, broccoli, carrots, okra, onions and strawberries as well as citrus, nuts and grapevines. Further areas of application are tobacco, young plantations and tree nurseries.
“In an integrated pest management program with Velum Prime, farmers will have a new choice for effective nematode control,” Klaus Koetting added. “This innovative combination enhances root health and helps farmers establish strong plant growth for higher yields and better harvests.” This combination of products also offers farmers the benefit of nematode control while lowering their dependency on older and considerably less environmentally friendly products.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.